The Mitsubishi Life Science Institute has launched a clinical trial with MUSE cells (multi-lineage differentiating stress enduring cells) for the treatment of acute myocardial infarction in January, 2018. Now, LSI annunces a clinical trial CL2020 with MUSE cells targeting patients with cerebral infarction. In this trial, MUSE cells will be administered intravenously.
LSI news release, September 3, 2018
Mitsubishi LSI announces clinical trial for treatment of cerebral infarction with MUSE cells